Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.

The Annals of Pharmacotherapy
Judy W M ChengSarah A Spinler

Abstract

Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.

References

Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Mar 15, 2018·Journal of the American College of Cardiology·Stephen J GreeneJaved Butler
Aug 5, 2018·Journal of the American College of Cardiology·Thomas A Zelniker, Eugene Braunwald
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jun 7, 2019·Circulation·Shannon M DunlayUNKNOWN American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Car
Jun 7, 2019·Drugs·Anthony Markham, Susan J Keam
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation

Clinical Trials Mentioned

NCT03057977
NCT03057951
NCT03619213
NCT03521934
NCT03036150
NCT03594110
NCT03315143

Software Mentioned

DAPA
CREDENCE
HF
CANVAS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.